<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 346 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page345.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=346">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 346 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 346</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=346"><img src="../thumb/346.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Endocrine System - 19.7 / 19.8                                                 2020-04 / 309
       picog./ ml for each follic.&gt;18 mm) the final phase of maturat.of fol-  flush., bone pain incr, breast swell.& tendern., skin rashes, arthralg.,   natural/artific. induc.postmenopaus.status prev.treat.with anti-oes-
       lic.is induc.by admin.of hCG. Oocyte retriev.perform.34-35 hrs.later.  spin.cord compress., ureter. obstruct., pituit.apoplexy, reduc.gluc.tol.  trog., pre-op ther.in postmenopaus.women with localis.horm.recept.
       Contraindications: Tumours of ovary/breast/ uterus/ testis/ pituit./   Special precautions: Poss.ureter.obstruct./spin. cord compress.  positive breast Ca allow. subseq.breast-conserv.surg.in women not
       hypothalam., pregn.& lactat., undiagnos.vag.bleed., prim.ovar.fail.,   in males, proven non-horm.depend. Ca pts.less likely to respond,   origin. consid.for this type of surg.
       ovar. cysts /enlarg.ovar.not relat.to PCOD, malformat.of sex.organs   incr.uter.cerv.resist. when dilat., safety & effic.for gynaecolog.con-  (S4) TABS, 42/21.12/0323
       /uter.fibroid tumours incompat.with pregn.  dits. for periods exceed.6 mnths.not est., combin.with tamoxifen in   715704-001: 2,5 mg, 30, R495,28
       Side effects: Ectop. pregn., multiple gestat., ovar. enlarg., unwant.  breast Ca pts.may reduc.bone min. loss, addit.HRT dur.endometrios.  Dosage: Adults & elderly: 2,5 mg once dly. Cont treatm.until tu-
       ovar. hyperstimulat., ovarian hyperstimulation syndrome (OHSS),   treatm.in pts. receiv. 3,6 mg strength to reduc.bone min.density loss   mour progress.evid.
       arterio-thromboembol., inj.site.reacts.  & vasomot.sympts., no exper.in HRT use with 10,8 mg admin., in   Contraindications: Premenopaus.endocrine status, safety in
       Warnings & special precautions: Use with concom. clomif.citr.  men a biphosphon.combin.with LHRH agon.may reduc.bone min.  pregn.& lactat.not est., sev.hepat. funct. impairm. (Child Pugh C),
       may enhance follic.resp., high. dos.may be necess.to achieve adeq.  loss, monit.bld. gluc. as reduct.in gluc.tol.observ.in males, excl.   ren.funct.impairm. (creatine clear.&lt;10 ml/min.), childr.
       follicul. respon. aft.pituit.desensitisat.induc.by a GnRH agon., excl.  pregn. prior to assist.reproduct.use in which case spec. supervis.  Side effects: UTI, tumour pain, leucopen., angioed., anaphylact.
       pres.of uncontroll.non-gonad. endocrinopath. incl.thyr./adren./pituit.  neccess., ovar.hyperstimulat.syndr. with concom.gonadotroph., in   reacts., anorex., incr.appet., hypercholesterolaem., gen./periph.
       disord.; multiple gestat.risk, perf. 1st inj.und.direct medic. supervis.,   assist.repro regimen in polycyst.ovar.syndr., use non-hormon. con-  oed., psych. disords., CNS effs., headache, dizzin., dysaesthes.,
       confirm intra-uterine pregn., rates of pregn. loss in ART high.than in   tracept. dur.ther., hypertens.  CVA, cataract, eye irrit., blurr.vis., palpitat., tachycard., thrombo-
       norm.populat., unwant. ovar.hyperstimulat.; discont.use, avoid pregn.   phlebit., hypertens., ischaem. card. events, pulm. embol., arter.
       & withold hCG if unwanted ovar. hyperstimulat. occ.        thrombos., cerebrovasc. infarct., dyspn., cough, GI disturbs., incr.
       SUPREFACT, Sanofi-Aventis     19.8   Hormone inhibitors    hepat.enzym., hepatit., alopec., incr.sweat., skin reacts.incl.tox.epi-
                                                                  derm.necrolys./ erythema multiforme, arthralg., myalg., bone pain/
       Buserelin acetate                                          fract., osteoporos., arthrit., incr.urin.freq., vag.bleed./ disch./ dryn.,
       Indications: Advanc.prostat.Ca where suppress. of testoster.  AVODART (MDR Listing)  breast pain, hot flush., fatig.incl. asthen./ malaise, pyrex., mucos.
       product.indicat.              DUODART (MDR Listing)        dryn., thirst, weight chang.
       (S4) 3-MONTH DEPOT IMPLANT. 32/21.10/0345  FIRMAGON (MDR Listing)  Special precautions: Imp.ren.funct., no exper.in combin. with
       886819-006: 9,9 mg, 1 applic.consist.of 3, identic. rods, R6 071,29  NORPROLAC (MDR Listing)  other anti-cancer agents.
       Dosage: Admin.every 3 calend.mnths.maint.3 mnthly rhythm. Inject   SANDOSTATIN (MDR Listing)
       one implant SC in abdom. wall. Five days bef.1st implant admin.an   SENSIPAR (MDR Listing)  ANDROCUR, Bayer [P/S]
       anti-androgen accord.to manuf.instructs.which is to be cont. dur.1st   SIGNIFOR (MDR Listing)  Cyproterone acetate
       3-4 wks.of treatm. Loc.anaesthet.use bef.inj.at discret.of pt/physc.   ZYTIGA (MDR Listing)  Indications: Women: Sev.signs of androgenizat. Men: Reduct.
       Treatm.durat.determ. by physc.  ACCORD ANASTROZOLE, Accord.  of drive in sexual deviat., antiandrog. treatm.of inop. prostate Ca.
       Contraindications: Effic.not been est.aft.surg. remov. of testes/   (S4) TABS, [P/S] R/21.12/160
       treatm.with oestrog.ther.     Anastrozole.                 703583-018: 50 mg, 20, R740,79
                                     Indications: Early & advanc.breast Ca in postmenopaus. women,
       Side effects: Occur./exacerbat.bone pain in bone metastas., neu-  Dosage: Women:
       rolog.deficit signs., micturit. impairm., hydronephros., lymphostas.,   effic.not demonstrat.in oestrog. recept.negat.pts.unless prev.posit.  Sev.androgenisat.signs: Child bear.pts.always to have complet.
       thrombos. with pulm.embol., incr.in tumour pain/deteriorat.in gen.   clinic. respons.to tamoxifen report.  one full cycle of oral combinat. contracept.bef.commenc.treatm.
       well-being even with concom.anti-androgen ther., hot flush., loss   (S4) TABS. 42/21.12/0259  Admin.2x50 mg tabs dly from 5th-14th day cycle. Cont.this regim.
       of potency/libido, gynaecomast., oed.of ankles/lower legs, chang.  715703-001: 1 mg, 30, R206,94  every 28 days (ie.usual.menstr.cycle durat.). Follow. clinic.improvem.
       in scalp & body hair, deteriorat.BP lev.in hypertens. pts., skin red-  Dosage: Adults incl.elderly: 1 tab.once dly.  dly.dos.dur.combin.OC treatm.may be reduc.to 1 or ½ tab. If Androcur
       den./itch., rash incl.urticar., allerg. asthma with dyspn., anaphy-  Contraindications: Pre-menopaus.women, pregn. & lactat., sev.  tab. miss.therapeut.effic.poss.dimin & intermenstr. bleed. poss.but
                                     ren.impairm., mod.to sev. hepat. dis.
       lact./anaphylactoid shock, thirst, appet.changes., gluc.tol.reduc.,   miss.tab.to be disregard.& tab.tak resum.at reg.time.
       deteriorat. metabol.contr.in diabet., thrombocytopen., leucopen.,   Side effects: Leucopen., allerg.reacts,incl. angioed./ anaphylax.,   Post menopaus./aft.hysterect: Admin.alone. ½-1 tab dly x21 days
                                     hot flush., oed., thrombophlebit., hepatobil.disords.incl.hepatit.,
       chang.in bld.lipids, ser. lev.of liv. enzyme/bilirub.incr., headaches,   follow.by 7 day tab.free interv.
       palpitat, dizzin, drowsin., nervousn., anx., developm./ worsen. of   joint pain/stiffn., myalg., arthralg., asthen., fev., flu-like syndr., vag.  Dosage: Men:
                                     bleed./dryn., hair thin., skin reacts. incl.erythem. multiforme/Stev.
       depress., sleep/memory/ conc. disturbs., emot.instabil., tinnit.,   Sex.drive reduct: Init.1 tab.2xdly.incr.if necess.to 2 tabs 2xdly/
       hear.disords., impair. vis., feel of press.behind eyes, GI disturbs.,   Johns. syndr., GI disturbs., headache, carpal.tunnel syndr., dizzin.,   or even 3xdly.for short per.. Maint.on low.poss.dose. ½ tab 2xdly.
                                     CNS effs., hypercholesterolaem.
       weight chang., musculoskelet.discomf.& pain, decr. bone dens.,   poss.suffic. Reduc.dos. grad.pref.by ½ tab.at interv.of sev.wks. Ad-
       tiredn., pain/loc.reacts.at inj.site, pituit. adenom.with long term   Special precautions: Poss.bone miner.dens. reduct. with incr.  min.over protract.time pref.in conjunct.with psychotherapeut. meas.
       treatm., concom. anti-androg. dur. init.treatm.phase may avoid   fract.risk, not recomm.in childr., lact. intol., biochem.confirmat.of   Antiandrog.treatm.of inop.prostate Ca: 2 tabs 2-3xdly.(ie.200-
       init. second. reacts., in case of anaphylact/ anaphylactoid reacts.  menopause if in doubt.  300 mg/day). Do not interrupt. treatm./ reduc.dos.aft.improvem./
       remov.implant surg.           Drug interactions: Tamoxifen &/other oestrog. contain. ther.  remiss.
       Special precautions: Monit.BP in hypertens.& bld. gluc.in dia-  would dimin.pharm.act.  (S4) TABS, 29/21.12/0515
       bet.pts., depress.hist.       ACCORD BICALUTAMIDE, Accord [P/S]  Indications: Inop.prostate Ca
       Drug interactions: Antidiabet.agent eff.poss. attenuat.  Bicalutamide.  836281-004: 100 mg, 60, R3 872,39
       ZOLADEX, AstraZeneca [P/S]    Indications: Advanc.prostate Ca in combin.with LHRH analog.   Dosage: Admin.after meals
                                                                  Antiandrog.treatm.of inop.prostate Ca: 100 mg 2-3xdly.
       Goserelin.                    ther./surg.castrat.          (ie.200-300 mg/day). Do not interrupt. treatm./ reduc.dos.aft.im-
       Indications: Prostate Ca suit.for hormon. manipulat., advan./  (S4) TABS. 41/21.12/0431  provem./remiss.
       metast.breast Ca suit.for hormon. manipulat.in pre-& peri-meno-  715705-001: 50 mg, 30, R577,55  To reduc.init.incr.of male sex hormon.in treatm. with GnRH
       paus. women, adjuv.to surg.&/or radiother.in pre-menopaus. women   Dosage: Begin 3 days bef.LHRH ther./same time as surg.castrat.  agonists: 100 mg 2xdly alone for 5-7 days follow.by 100 mg 2x/day
       with oestrog.recept.posit.early breast Ca suit.for hormon.manipulat.  Adult males incl.elderly: 1 tab once dly.  for 3-4 wks. tog. with GnRH agonist recomm.dos.
       as alternat.to chemother., endometrios., reduct.of uter.fibroid size   Contraindications: Fem., childr., safety & effic.in pregn.& lac-  Hot flushes in pts.und.GnRH analog.treatm. aft.orchidectomy:
       bef.surg., endometr.thin., assist.reproduct.  tat.not est.  100 mg 1-2xdly. (ie.100-200 mg/day).
       (S4) INJ. U/21.10/163         Side effects: Bld.dyscras., hypersens.reacts., anorex., diab.mel-  Contraindications: Pregn.& lactat., liv.dis., Dubin Johnson/ Rotor
       781215-005: 3,6 mg, sngl.dos.pre-fill.syr., R2 427,46  lit., hyperglycaem., depress., CNS effs., dizzin., hypertens., URTI,   syndr., jaund.hist., persist. prurit. dur.prev.pregn., Herpes of pregn.,
       Dosage: No dos.adjustm.necess.in ren./hepat. impairm.  hoarsen., cough, shortn. of breath, sore throat, sneez., interstit.  prev./exist. liv. tumours (if not due to Ca prostate metastas.in men),
       Adults incl.elderly: Admin 3,6 mg SC into ant. abdom. wall every   lung dis., dyspn.incl.fatalit., GI disords.incl.bleed., hepat. chang/fail.,   wasting dis.(except.inop. prostate Ca in men), sev. chron.depress.,
       28 days. Treat gynaecolog. condits. for max.6 mnths.  hepatit., methaemoglobinaem., alopec., hirsutism, hair re-growth,   pts.with hist.of prev.or exist.thrombo-embol.process./diabet.with
       Endometr.thinn: Admin. 1or 2x 3,6 mg SC 4 wks. apart. When 3,6   skin reacts., sweat., haematur., noctur., gynaecomast., breast ten-  vasc. chang./ sickle-cell anaem.
       mg inj.is admin.perform surg.at 4wks. 2  depot maybe reqd.for pts.  dern., impot., decr.libido, asthen., oed., fev., chest pain, chills, flu-  Side effects: Dos.relat.direct hepat.toxic.incl. jaund./hepatit.& liv.
                        nd
       with large uterus/to allow for flex.timing of surg. When 2x 3,6 mg inj.  like syndr., weight gain.  fail.with fatalit., liv.tumours, shortn.of breath at high dos., thrombo-
       is admin.surg.should be perform.within 2 wks.aft.admin.second inj.  Special precautions: Monit.prothromb.time with coumar.anti-  embol. events., changes in RBC numb., reduc.adrenocortic. funct.,
       Assist.repro: Perform superovulat.& oocyte retriev. once pituit.  coags., mod.to sev.hepat.impairm., per. liv.funct.tests advis., dis-  incr.prolact.lev., weight incr./decr., decr. libido, incr.libido in women,
       down.regulat.achiev.          cont.ther.if hepat. chang. sev., meds.metabol.by cytochrome P450.  erect.dysfunct., depress., restlessn., skin rash, osteoporos.in males,
       (S4) INJ. 30/21.10/0100       Drug interactions: Poss.displac.warfar.from its prot.bind. sites,   ovulat.inhibit.in women, revers.inhibit.of spermatogen.in males,
       834270-005: 10,8 mg, sngl.dos.pre-fill.syr., R6 130,94  midazolam AUC incr., concom. meds. that may inhib.oxidat.of   breast tendern., gynaecomast., enlarg.mamm.glands, galactorrh,
       Indications: Males: Prost.Ca suit.for hormon. manipulat. Females:   agent eg.ketoconazole & cimetidine which could theoretic. incr.  benign nodul., fatig., hot flush.& sweat.in males
       Clinic.sympt.relief of endometrios. & uter.fibroid size reduct.bef.  plasma conc.  Special precautions: Do not give bef.conclus.of puberty, monit.liv.
       surg.as temporar.use.         ACCORD FINASTERIDE, Accord [P/S]  funct.pre-treatm.& if S&S suggest. of hepatotoxic.occur ther.should
       Dosage: No dos.adjustm.necess.in ren./hepat. impairm./elderly  Finasteride.  norm.be discont., cons.risk:benef.ratio if hepatotox.confirm. by an-
       Adult men incl.elderly: 10,8 mg SC into ant. abdom. wall eve-  Indications: Benign prostat.hyperplas.(BPH).  other cause eg metastat.dis., sex.steroids can promote growth of
       ry 3 mnths                    (S4) TABS. 43/21.12/0056     cert.horm.depend.tiss.& tumours., consid.shortn.of breath poss.due
       Adult women: 10,8 mg SC into ant.abdom.wall every 12 wks.  716739-001: 5 mg, 30, R233,90  to stimulat. eff.of progesterone & synthet. progesterone on breath.,
       Contraindications: Pregn.& lactat., childr.  Dosage: 5 mg dly. 6-12 mnth.ther.poss.necess.to assess respons.  incr.risk of thromboembol. events with prev.hist.thereof/CVA hist./
       Side effects: Bone min.densit.loss., hypersens. reacts. incl.anaphy-  Contraindications: Pregn./poss.pregn., use in women/ childr.  advanc.malign., caref.risk:benef.eval.in prostat.Ca pts.with thrombo-
       lax./bronchosp.& angioed., incr. bld. lipids, loc.reacts., interstit.lung   Side effects: Freq: Impot., decr.libido, ejaculat. disords., testic.pain.   embol.hist.&/ sickle-cell anaem./diab.with vasc.chang., incr.prolact.l
       infiltr., joint effus./ swell., carpal tunn.syndr., erythema multiforme.   Less.freq: Breast enlargem./ tendern., skin reacts., hypersens. re-  ev.with high dos., always excl.poss.pregn.in women & investig.if no
       Females: Headaches, depress., loss of libido, breast size chang.,   acts.incl. fac.& lip swell. Freq.unknown: Palpitat., incr.liv.enzym.  bleed.occurs dur.inact. tab.phase of OC treatm., reduc.sex.drive/po-
       vag.dryn., sweat., trans. systol.& diastol.BP incr., hot flush., incr.S&S   Warnings and special precautions: Poss. abnormalit. to ext.   tency & inhibit.gonad.funct.is revers.on discontin., CV dis., ischaem.
       in breast Ca, hypercalcaem.on init.ther.in breast Ca pts.with bone   genital.of male foetus, expos.to crush./ brok.tabs.by pregn./poss.  heart dis., cerebrovasc.dis., hypertens., monit.adrenocortic.funct.
       metastas., ovar.hyperstimulat.syndr., ovar.cyst format., pelv.pain   pregn.women, elderly (pts.old.than 70 yrs.), monit.for obstruct.   & RBC count, strict med.supervis.of diab., investig.persist./recurr.
       relat.to haemorrh.into uter.fibromyoma, dyspareun., dysmenorrh.,   uropathy, prostate Ca screen prior to init.& dur. ther., eval.pts with   bleed.at irreg.interv.in women, alcoh.diminish. sex.drive reduct.eff.
       menorrhag., uter.& vag.bleed.in fibroid treatm., tempor.incr.in S &   sustain.incr.in S-PSA lev.caref., S-PSA values decr.in treat.pts., no   Drug interactions: Oral antidiab./insul.requirm. may change,
       S, variab.vag.bleed.& spott., fibroid degenerat.sympt., poss.enter.  clinic.benef.in pts. with prost.Ca, not known if excret.in breast milk.  strong CYP3A4 inhibit.metabol., CYP3A4 induc.may reduc.lev., sta-
       menopause & menses might.not return on cessat.of ther., median   tin assoc. myopathy/rhabdomyolys.incr.
       time for return of menses is 70 days from last inj. but may be prolong.  ACCORD LETROZOLE, Accord
       with 10,8 mg use, insom./ tiredn. & weight gain follow.reduct.of ser.   Letrozole  ANDROCUR DEPOT, Bayer [P/S]
       oestradiol, acne, seborrhoea, oily hair, hirsut., oed., migraine, confus.  Indications: First line treatm.in postmenpaus. women with ad-  Cyproterone acetate
       states. Males: Paraesthes., decr. potency, sex.dysfunct., sweat., hot   vance.breast Ca, hormone depend. advanc.breast Ca in women with   Indications: Reduct.of drive in male sex.deviat., inop. prostat.Ca.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page345.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page341.html">341</a>&nbsp;&nbsp;&nbsp;<a href="page342.html">342</a>&nbsp;&nbsp;&nbsp;<a href="page343.html">343</a>&nbsp;&nbsp;&nbsp;<a href="page344.html">344</a>&nbsp;&nbsp;&nbsp;<a href="page345.html">345</a>&nbsp;&nbsp;&nbsp;<a href="page346.html">346</a>&nbsp;&nbsp;&nbsp;<a href="page347.html">347</a>&nbsp;&nbsp;&nbsp;<a href="page348.html">348</a>&nbsp;&nbsp;&nbsp;<a href="page349.html">349</a>&nbsp;&nbsp;&nbsp;<a href="page350.html">350</a>&nbsp;&nbsp;&nbsp;<a href="page351.html">351</a>
             </td>
             <td width="35%"><a href="page347.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page347.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
